You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advancing a Glioma Immunotherapy
SBC: IN CYTU, INC. Topic: 102DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...
SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Structure activity relationship of small molecule inhibitors of human papillomavirus E protein will be tested
SBC: SUNNYLIFE PHARMA INC. Topic: NIAIDThe human papillomavirus HPV E protein is needed for viral replication Infection with high risk HPV types can progress to pre malignant lesions called dysplasias which over a period of years can eventuate in invasive and metastatic epithelial malignancies HPV E proteins bind to the ubiquitin ligase E AP and this complex targets p and other E binding proteins for proteasome mediated de ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza
SBC: EPIVAX, INC. Topic: NIAIDDESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Assay Platform for Measuring Endogenous Kinase Activity
SBC: Kinasense LLC Topic: 100DESCRIPTION provided by applicant Kinase inhibitors are an effective class of targeted therapy for oncology However heterogeneous patient response and acquired resistance continues to be a significant clinical and economic burden To overcome this problem drug developers are pursuing novel kinase inhibitors for existing kinase targets with new modes of inhibition and increased potency as wel ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel Bone-Targeting Combination Therapy for Osteosarcoma
SBC: MBC Pharma, Inc. Topic: 102DESCRIPTION provided by applicant The overall aim of this project is to evaluate the feasibility of using a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastases The conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate Ibandronate The novel co ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Integrated Framework for Simultaneous Generative Language Training and Progress Tracking for Minimally Verbal Children with Autism
SBC: SPEAK MODalities LLC Topic: NIDCDDESCRIPTION provided by applicant The proposed project will create novel tablet technology for speech and language learning in minimally verbal children with autism spectrum disorder ASD This research is directly related to a goal of The National Institute on Deafness and Other Communication Disorders NIDCD which calls for andquot developing speech and language interventions for nonverbal ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Chemical enhancement of CRISPR/Cas9 mediated site-specific genome engineering
SBC: NERX BIOSCIENCES, INC. Topic: 200DESCRIPTION provided by applicant Chemical enhancement of CRISPR Cas mediated site specific genome engineering Abstract Programmable nucleases including Zinc Finger Nucleases TALENs meganucleases and the CRISPR Cas system allow for site specific genome engineering The ability to make targeted genetic modifications has opened up a wide variety of options for scientists in industry and aca ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Micropatterned surfaces for minimizing percutaneous gastrostomy tube complications
SBC: Sharklet Technologies Inc. Topic: NICHDDESCRIPTION provided by applicant Enteral nutrition using feeding tubes provides a long term means of improving the nutritional status for infants and children with neurological syndromes cancer gastrointestinal disease cardiac disease and metabolic disease by allowing administration of feeding formula directly to the stomach through the upper abdomen More than pediatric percutaneo ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Higher Order Structure Analysis of Protein Therapeutics by Covalent Labeling MS
SBC: Reclaim Pharmaceutical Waste Management, LLC Topic: 100DESCRIPTION provided by applicant Protein therapeutics are the fastest growing segment of the pharmaceutical market accounting for one third of the overall late stage drug development pipeline and anticipated to represent of the total pharmaceuticals market value by However two significant challenges must be overcome to maximize patient benefit and access to biologic drugs Patient ...
SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health